Omicron could disrupt plans for leading drugs against COVID-19
The rapidly-spreading omicron variant may soon leave U.S. doctors without two of the standard treatments they've used to fight COVID-19.
Stay updated with breaking news from James Cutrell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The rapidly-spreading omicron variant may soon leave U.S. doctors without two of the standard treatments they've used to fight COVID-19.
“I think there’s going to be a shortage,” said Dr. Jonathan Li, director of the Harvard/Brigham Virology Specialty Laboratory. “We’re down to one FDA-authorized monoclonal antibody” with omicron because of the reduced effectiveness of Regeneron and Lilly’s drugs.
The shrinking toolbox of treatments is a reminder that the virus still has the upper hand in the U.S.
The rapidly-spreading omicron variant may soon leave U.S. doctors without two of the standard treatments they've used to fight COVID-19.
As strained U.S. hospitals brace for a new surge of COVID-19 cases caused by the fast-spreading omicron variant, doctors are warning of yet another challenge: the two standard drugs they've used to fight infections are unlikely to work against the new strain.